Most Recent Stories
More News– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching...
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both...
Barchart Research What to Expect from KURA Earnings KURA Generated May 11, 2026 Current Price $9.51 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 1.98% Kura Oncology's Commercial Transition...
Barchart Research What to Expect from KURA Earnings KURA Generated May 6, 2026 Current Price $9.56 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 1.98% Kura Oncology's Commercial Launch...
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated...
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30...